Personalized mechanical ventilation guided by ultrasound in patients with acute respiratory distress syndrome (PEGASUS): study protocol for an international randomized clinical trial
Jante S Sinnige,Marry R Smit,Aniruddha Ghose,Harm-Jan de Grooth,Theis Skovsgaard Itenov,Eleni Ischaki,John Laffey,Frederique Paulus,Pedro Póvoa,Charalampos Pierrakos,Luigi Pisani,Oriol Roca,Marcus J Schultz,Konstanty Szuldrzynski,Pieter R Tuinman,Claudio Zimatore,Lieuwe D J Bos,PEGASUS investigators,A K M Arif Uddin Ahmed,Mohammad Jhahidul Alam,Mohsammad Rafiqual Alam,Anjan Bal,Samarjit Barua,Rajdeep Biswas,Mohammed Abdur Rahaman Chowdhury,Safiqul Mostafa Chy,Satyajit Dhar,Pranay Kumar Dutta,Syeda Nafisa Khatoon,Ranjan Kumar Nath,Nahid Nowroz,Mithun Shil,Rachid Attou,Leonel Barreto Gutierrez,Keitiane Kaefer,Morten Bestle,Lars Hein,Thomas Hildebrandt,Jacob Jensen,Sanne Lauritzen,Ulf Pedersen,Lone Poulsen,Harry Giannopoulos,Katerina Vaporidi,Lauren Ferguson,Yvelynne Kelly,Sabina Mason,Aisling McMahon,Bairbre McNicholas,Daniele Biasucci,Gianmaria Cammarota,Maurizio Follino,Salvatore Grasso,Antonio Latela,Giovanna Magnesa,Fabrizia Massaro,Leonarda Maurmo,Marco Pezzuto,Savino Spadaro,Luigi Vetrugno,Massimo Zambon,Daan Filippini,Peter Klompmaker,Amne Mousa,Dominik Daszuta,Miłosz Jankowski,Irene Aragao,Heloisa Castro,Vasco Costa,Cristina Torrão,Toni Antoni,Marta Arroyo,Marta Briva,Nuria Duran,Marina García-de-Acilu,Gemma Goma,Ana Ochagavia,Michelle Chew,Mariangela Pellegrini,Gaetano Perchiazzi
DOI: https://doi.org/10.1186/s13063-024-08140-7
IF: 2.728
2024-05-07
Trials
Abstract:Background: Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. Identifying ARDS subphenotypes based on "focal" or "non-focal" lung morphology has the potential to better target mechanical ventilation strategies of individual patients. However, classifying morphology through chest radiography or computed tomography is either inaccurate or impractical. Lung ultrasound (LUS) is a non-invasive bedside tool that can accurately distinguish "focal" from "non-focal" lung morphology. We hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients leads to a reduction in 90-day mortality compared to conventional mechanical ventilation. Methods: The Personalized Mechanical Ventilation Guided by UltraSound in Patients with Acute Respiratory Distress Syndrome (PEGASUS) study is an investigator-initiated, international, randomized clinical trial (RCT) that plans to enroll 538 invasively ventilated adult intensive care unit (ICU) patients with moderate to severe ARDS. Eligible patients will receive a LUS exam to classify lung morphology as "focal" or "non-focal". Thereafter, patients will be randomized within 12 h after ARDS diagnosis to receive standard care or personalized ventilation where the ventilation strategy is adjusted to the morphology subphenotype, i.e., higher positive end-expiratory pressure (PEEP) and recruitment maneuvers for "non-focal" ARDS and lower PEEP and prone positioning for "focal" ARDS. The primary endpoint is all-cause mortality at day 90. Secondary outcomes are mortality at day 28, ventilator-free days at day 28, ICU length of stay, ICU mortality, hospital length of stay, hospital mortality, and number of complications (ventilator-associated pneumonia, pneumothorax, and need for rescue therapy). After a pilot phase of 80 patients, the correct interpretation of LUS images and correct application of the intervention within the safe limits of mechanical ventilation will be evaluated. Discussion: PEGASUS is the first RCT that compares LUS-guided personalized mechanical ventilation with conventional ventilation in invasively ventilated patients with moderate and severe ARDS. If this study demonstrates that personalized ventilation guided by LUS can improve the outcomes of ARDS patients, it has the potential to shift the existing one-size-fits-all ventilation strategy towards a more individualized approach. Trial registration: The PEGASUS trial was registered before the inclusion of the first patient, https://clinicaltrials.gov/ (ID: NCT05492344).